Cetirizine injection - JDP Therapeutics

Drug Profile

Cetirizine injection - JDP Therapeutics

Alternative Names: JDP-205; JDP-205 Al; JDP-207

Latest Information Update: 10 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator JDP Therapeutics
  • Class Acetic acids; Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypersensitivity

Most Recent Events

  • 30 May 2017 JDP Therapeutics announces intention to submit NDA to the US FDA for Hypersensitivity (acute urticaria) in first half of 2018
  • 01 Mar 2017 Phase-III clinical trials in Hypersensitivity in USA (IV) (NCT02935699)
  • 01 Mar 2017 JDP Therapeutics initiated enrolment in a phase III trial in Hypersensitivity in Canada (IV) (NCT02935699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top